Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829711 · ClinicalTrials.gov registry record · Phase 3
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
A Phase 3 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
NCT01829711 is a Phase 3 study that has completed, run by MedImmune. The registered enrollment target is 80 participants.
The verdict
NCT01829711, a Phase 3 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
Study Summary
Background: \- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results.
Interventions
- DRUG Moxetumomab pasudotox
- DRUG IV Bag Protectant for Moxetumomab pasudotox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-04-29 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829711
The ClinicalTrials.gov registry entry for NCT01829711 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moxetumomab pasudotox is the first listed.
NCT01829711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829711 about?
NCT01829711 is a clinical study titled "Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia". Background: \- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I t...
What is the current status of trial NCT01829711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2013-04-29. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT01829711?
The interventions under investigation include: Moxetumomab pasudotox (DRUG), IV Bag Protectant for Moxetumomab pasudotox (DRUG).
Who is sponsoring clinical trial NCT01829711?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.